Novel Oncolytic Immunotherapy Aims to Address Unmet Therapeutic Need for Anti–PD-1 Refractory Tumors
OncLive,
Investigators have taken strides to genetically engineer novel oncolytic immunotherapies that synergize with existing…
Investigators have taken strides to genetically engineer novel oncolytic immunotherapies that synergize with existing…
Summary Replimune is developing a handful of oncolytic immunotherapies therapies targeting cancers.
RP1: Initial Data from Phase 1 part of Phase 1/2 clinical trial alone and in combination with nivolumab expected to be…
RP1: Initial Data from Phase 1 part of Phase 1/2 clinical trial alone and in combination with nivolumab expected to be…